Rapidly fatal advanced EGFR-mutated lung cancers and the need for rapid tumor genotyping in clinical practice

Ítems similars

• Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR‐G719A and Other Uncommon EGFR Mutations
  per: Sehgal, Kartik, et al.
  Publicat: (2020)
• The Rapidly Evolving Landscape of Biomarker Testing in Non-Small Cell Lung Cancer
  per: VanderLaan, Paul A., et al.
  Publicat: (2020)
• De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: lack of response to EGFR inhibitors
  per: Le, Xiuning, et al.
  Publicat: (2015)
• Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers
  per: Rangachari, Deepa, et al.
  Publicat: (2015)
• Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% expression in lung adenocarcinoma
  per: Rangachari, Deepa, et al.
  Publicat: (2017)